ENZALUTAMIDE [XTANDI] -XTANDI 40MG
DESCRIPTION
Xtandi containing Enzalutamide is also categorized as an anti-androgen chemo medicine. Xtandi 40mg is not self medication; it is used under the knowledge of medical oncologist. |
| Xtandi 40mg |
XTANDI 40MG TABLET USES
Xtandi 40mg tablets are prescribing for; Metastatic or long lasting castration resistant prostate cancer.
XTANDI 40MG TABLET MECHANISM
Xtandi 40mg containing anti-androgen agent like Enzalutamide, it expels an anti-tumor activity in different steps. Xtandi 40mg tablets are interfere in androgen receptor signaling pathway, which prohibiting androgen binding to androgen receptors leads to androgen receptor nuclear translocation inhibition and interact with DNA. The major metabolite of Xtandi is N-desmethyl Enzalutamide which is similar to Enzalutamide activity. The anti-tumor activity of Xtandi is exposed by depleting the multiplication and persuades cell lysis in prostate cancer cells.
 |
| Xtandi 40mg |
PHARMACOKINETICS
After an oral administration of Xtandi 40mg tablets (160mg of dose), undergoes ADME process and exhibits activity. The peak plasma concentration time of Xtandi occurs at 1 hour with the range of 0.5 to 3 hours). The steady state of Xtandi occurs in day 28. The volume of distribution occur after single dose of Xtandi is 110LXtandi has highly bounds to the human plasma protein with the range of 97 to 98%. The major metabolite of Enzalutamide is N-desmethyl Enzalutamide has 95% bound to human plasma protein. The most important isoenzymes responsible for the metabolism of Enzalutamide are CYP2C8 & CYP3A4. CYP2C8 is involved in the formation of an active metabolite N-desmethyl Enzalutamide. Xtandi is majorly excreted through liver metabolism, 71% of metabolite present in urine and 14% in feces.
DOSAGE MANAGEMENT
The usual recommended dosage of Xtandi is 160mg, but available strength of Xtandiis 40mg. Four tablets of Xtandi 40mg should be taken at a time as a single dose.Xtandi tablet should be administered with or without food. Dosing alteration: In ≥ grade 3 toxicity or extreme side effects: Postpone the dose ofXtandi for 1 week or as far as symptoms progress to ≤ grade 2, continue at the same or reduced to 120mg or 80mg.
Concurrent use with strong CYP2C8 inhibitors:
In case of combination with strong CYP2C8 inhibitors, diminish the dose of Xtandi to 80mg as a single dose. Concurrent use with strong CYP3A4 inducers: In case of combination with strong CYP3A4 inducers, increasing the dose of Xtandi 160mg to 240mg as a single dose.
PRECAUTIONS
XTANDI 40MG TABLETS SAFETY PRECAUTIONS
The major adverse effect during the therapy of Xtandi tablets are;
SEIZURE
Seizure may produce during the treatment with Xtandi 40mg tablets, if seizure occurs the treatment should be discontinued until seizure resolved. To avoid this condition patient should be counsel about the problems occurred during the therapy before starting the treatment. Seizure may leads to loss of consciousness.
POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME PRES
Patient who are all taking Xtandi tablets acquired PRES, is a neurological problem produce symptoms like headache, lethargy, confusion, loss of vision, other neurological problems related with hypertension.
Seizure may produce during the treatment with Xtandi 40mg tablets, if seizure occurs the treatment should be discontinued until seizure resolved. To avoid this condition patient should be counsel about the problems occurred during the therapy before starting the treatment. Seizure may leads to loss of consciousness.
POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME PRES
Patient who are all taking Xtandi tablets acquired PRES, is a neurological problem produce symptoms like headache, lethargy, confusion, loss of vision, other neurological problems related with hypertension.
SIDE EFFECTS
XTANDI 40MG TABLETS CAUSING SIDE EFFECTS
Asthenia
Peripheral edema
Back pain, arthralgia
Musculoskeletal pain
Muscular weakness Musculoskeletal stiffness
Diarrhea
Headache
Dizziness
Spinal cord compression
Caude equine syndrome
Paresthesia
Mental disorders
Hot flush
Hypertension
Insomnia
Anxiety
Hematuria
Pollakiuria
Non pathologic fractures
Pruritus Dry skin
EpistaxisHypoesthesia
Respiratory tract infections
Peripheral edema
Back pain, arthralgia
Musculoskeletal pain
Muscular weakness Musculoskeletal stiffness
Diarrhea
Headache
Dizziness
Spinal cord compression
Caude equine syndrome
Paresthesia
Mental disorders
Hot flush
Hypertension
Insomnia
Anxiety
Hematuria
Pollakiuria
Non pathologic fractures
Pruritus Dry skin
EpistaxisHypoesthesia
Respiratory tract infections
PREGNANCY & LACTATION:
The pregnancy category of Xtandi tablet is X Xtandi tablets are contraindicated to pregnancy conditions; it may cause fetal harm even to death. Xtandi tablets are contraindicated in lactation period, breast feeding should not be recommended.STORAGE
The storage condition of Xtandi tablets container at 20°C to 25°C (68°F to 77°F). Container should be kept at dry and cool place.MISSED DOSE
vXtandi is a chemo tablets, if patient fail to take the dose of Xtandi tablets must be consult with medical oncologist and take the dose within a time. In any other way the missed dose should be avoid and follow the regular dosing schedule.OVER DOSAGE
In case of over dosage of Xtandi tablets, patients must provided with some supportive measures and discontinue the therapy. The half life of Xtandi is occurs for 5.8 days. Seizure is the major adverse effect occurred due to over dosage of Xtandi . Seizure is not described at ≤240mg daily; since three seizures occurs at 360mg, 480mg and 600mg daily.CONTACT US
MAILID : millionhealthpharmaceuticals@gmail.comPHONE NO : +91-9940472902
WEBSITE : https://millionpharma.com/enzalutamide-40mg.php
Comments
Post a Comment